<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01191229</url>
  </required_header>
  <id_info>
    <org_study_id>Tecnis One-Piece MF IOL</org_study_id>
    <nct_id>NCT01191229</nct_id>
  </id_info>
  <brief_title>Prospective Evaluation of Visual Outcomes With Tecnis One-Piece Multifocal Intraocular Lenses Compared With Patients Previously Implanted With Crystalens Aspheric Optic (AO)</brief_title>
  <official_title>Prospective Evaluation of Visual Outcomes With Tecnis One-Piece Multifocal Intraocular Lenses Compared With Patients Previously Implanted With Crystalens AO</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovative Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovative Medical</source>
  <brief_summary>
    <textblock>
      The study is being conducted to collect information about visual outcomes and participant&#xD;
      satisfaction with the Tecnis One-Piece Multifocal (MF) Intraocular Lenses (IOLs) compared&#xD;
      with participants previously implanted with Crystalens Aspheric Optic (AO) IOLs. The U.S.&#xD;
      Food and Drug Administration (FDA) has cleared the Tecnis One-Piece MF IOL for visual&#xD;
      correction of aphakia (replacing a removed lens in the eye) in adults.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incision size</measure>
    <time_frame>1 year</time_frame>
    <description>Part 1 Only:&#xD;
The primary outcome measure is incision size at three points:&#xD;
Immediately after application of the keratome blade Post phacoemulsification Post Tecnis IOL implantation Target refraction vs. achieved&#xD;
Part 1 and 2:&#xD;
UCVA data at distance, intermediate, and near Near vision will be measured in mesopic and photopic conditions standardized with light meter BCVA at distance and near Enhancement rates Spectacle independence questionnaire and patient satisfaction Incidence of adverse events</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>To Collect Information About Visual Outcomes and Participant Satisfaction</condition>
  <arm_group>
    <arm_group_label>Tecnis One-Piece MF IOL</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>It is planned that about 25 people who are at least 18 years old who are scheduled to have the Tecnis One-Piece Multifocal Intraocular Lenses placed into their eyes after cataract surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crystalens AO</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>It is planned that about 25 people who are at least 18 years old and have been implanted with Crystalens AO</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Tecnis one-piece MF IOL</intervention_name>
    <description>25 patients to be implanted after cataract surgery</description>
    <arm_group_label>Tecnis One-Piece MF IOL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Crystalens AO</intervention_name>
    <description>25 patients that are previously implanted</description>
    <arm_group_label>Crystalens AO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Key Inclusion Criteria for Part 1:&#xD;
&#xD;
               -  Age 18 or greater&#xD;
&#xD;
               -  Bilateral cataracts for which phacoemulsification extraction and posterior IOL&#xD;
                  implantation has been planned for both eyes&#xD;
&#xD;
               -  Visual potential of 20/30 or better in each eye after cataract removal and IOL&#xD;
                  implantation&#xD;
&#xD;
               -  Preoperative best-corrected distance visual acuity (BCDVA) worse than 20/40&#xD;
                  Snellen&#xD;
&#xD;
               -  Naturally dilated pupil size (in dim light) &gt; 3.5 mm (with no dilation&#xD;
                  medications) for both eyes&#xD;
&#xD;
               -  Preoperative corneal astigmatism of 1.5 D or less&#xD;
&#xD;
               -  Clear intraocular media other than cataract&#xD;
&#xD;
               -  Availability, willingness, and sufficient cognitive awareness to comply with&#xD;
                  examination procedures&#xD;
&#xD;
        Inclusion Criteria for Part 2&#xD;
&#xD;
          -  At least 18 years of age&#xD;
&#xD;
          -  Underwent bilateral implantation with Crystalens AO at least 6 months previously&#xD;
&#xD;
          -  Visual potential of 20/30 or better in each eye after cataract removal and IOL&#xD;
             implantation&#xD;
&#xD;
          -  Preoperative best-corrected distance visual acuity (BCDVA) worse than 20/40 Snellen&#xD;
&#xD;
          -  Naturally dilated pupil size (in dim light) &gt; 3.5 mm (with no dilation medications)&#xD;
             for both eyes&#xD;
&#xD;
          -  Preoperative corneal astigmatism of 1.5 D or less&#xD;
&#xD;
          -  Clear intraocular media other than cataract&#xD;
&#xD;
          -  Availability, willingness, and sufficient cognitive awareness to comply with&#xD;
             examination procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Key Exclusion Criteria for Part 1:&#xD;
&#xD;
               -  Use of systemic or ocular medications that may affect vision&#xD;
&#xD;
               -  Acute or chronic disease or illness that would increase risk or confound study&#xD;
                  results (e.g. diabetes mellitus, immunocompromised, etc.)&#xD;
&#xD;
               -  Subjects with diabetes mellitus&#xD;
&#xD;
               -  Uncontrolled systemic or ocular disease&#xD;
&#xD;
               -  History of ocular trauma or prior ocular surgery&#xD;
&#xD;
               -  Amblyopia or strabismus&#xD;
&#xD;
               -  Known pathology that may affect visual acuity; particularly retinal changes that&#xD;
                  affect vision (macular degeneration, cystoid macular edema, proliferative&#xD;
                  diabetic retinopathy, etc.)&#xD;
&#xD;
               -  Diagnosed degenerative visual disorders (e.g. macular degeneration, or other&#xD;
                  retinal disorders) that are predicted to cause future acuity losses to a level of&#xD;
                  20/30 or worse&#xD;
&#xD;
               -  Patients with forme fruste keratoconus or keratoconus&#xD;
&#xD;
               -  Subjects who may be expected to require retinal laser treatment or other surgical&#xD;
                  intervention&#xD;
&#xD;
               -  Capsule or zonular abnormalities that may affect postoperative centration or tilt&#xD;
                  of the lens (e.g. pseudoexfoliation syndrome)&#xD;
&#xD;
               -  Pupil abnormalities (non-reactive, tonic pupils, abnormally shaped pupils, or&#xD;
                  pupils that do not dilate at least 4.0 mm under mesopic/scotopic conditions)&#xD;
&#xD;
               -  Contact lens usage within 6 months for PMMA contacts lenses, 1 month for gas&#xD;
                  permeable lenses or 1 week for extended-wear and daily-wear soft contact lenses&#xD;
&#xD;
               -  Requiring an intraocular lens &lt;15.0 or &gt;26.0 diopters&#xD;
&#xD;
        Exclusion Criteria for Part 2&#xD;
&#xD;
          -  Diagnosed degenerative visual disorders (e.g. macular degeneration, or other retinal&#xD;
             disorders) that are predicted to cause future acuity losses to a level of 20/30 or&#xD;
             worse&#xD;
&#xD;
          -  Patients with forme fruste keratoconus or keratoconus&#xD;
&#xD;
          -  Subjects who may be expected to require retinal laser treatment or other surgical&#xD;
             intervention&#xD;
&#xD;
          -  Capsule or zonular abnormalities that may affect postoperative centration or tilt of&#xD;
             the lens (e.g. pseudoexfoliation syndrome)&#xD;
&#xD;
          -  Pupil abnormalities (non-reactive, tonic pupils, abnormally shaped pupils, or pupils&#xD;
             that do not dilate at least 4.0 mm under mesopic/scotopic conditions)&#xD;
&#xD;
          -  Requiring an intraocular lens &lt;15.0 or &gt;26.0 diopters Exclusion Criteria for Part 2&#xD;
&#xD;
          -  Diagnosed degenerative visual disorders (e.g. macular degeneration, or other retinal&#xD;
             disorders) that are predicted to cause future acuity losses to a level of 20/30 or&#xD;
             worse&#xD;
&#xD;
          -  Patients with forme fruste keratoconus or keratoconus&#xD;
&#xD;
          -  Subjects who may be expected to require retinal laser treatment or other surgical&#xD;
             intervention&#xD;
&#xD;
          -  Capsule or zonular abnormalities that may affect postoperative centration or tilt of&#xD;
             the lens (e.g. pseudoexfoliation syndrome)&#xD;
&#xD;
          -  Pupil abnormalities (non-reactive, tonic pupils, abnormally shaped pupils, or pupils&#xD;
             that do not dilate at least 4.0 mm under mesopic/scotopic conditions)&#xD;
&#xD;
          -  Requiring an intraocular lens &lt;15.0 or &gt;26.0 diopters&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>JacksonEye</name>
      <address>
        <city>Lake Villa</city>
        <state>Illinois</state>
        <zip>60046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>August 19, 2010</study_first_submitted>
  <study_first_submitted_qc>August 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2010</study_first_posted>
  <last_update_submitted>June 13, 2012</last_update_submitted>
  <last_update_submitted_qc>June 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 14, 2012</last_update_posted>
  <responsible_party>
    <name_title>Mitch Jackson, MD</name_title>
    <organization>JacksonEye</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

